ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Painter Is AMA President-Elect; FDA Approves Taxol; Protocol Enrolls 150-200 A Month

August 14, 1992

NCI Programs: First Raid Awardees, Drug Development Projects, Listed

March 26, 1999

In Brief: James Wallace Named CALGB Executive Officer; Gritz Receives First Joseph Cullen Award

September 11, 1992

NCCS Networker Volume 8 Issue 2, Summer 1994

June 13, 1994

New ACS Awards Total $18.4 Million

February 23, 1979

Construction Gets Extra $1 Million, Six Grants Okayed

May 29, 1981